The Bloom’s syndrome protein, BLM, is a member of the conserved RecQ helicase family. Although cell lines lacking BLM exist, these exhibit progressive genomic instability that makes distinguishing primary from secondary effects of BLM loss problematic. In order to be able to acutely disable BLM function in cells, we undertook a high throughput screen of a chemical compound library for small molecule inhibitors of BLM. We present ML216, a potent inhibitor of the DNA unwinding activity of BLM. ML216 shows cell-based activity, and can induce sister chromatid exchanges, enhance to the toxicity of aphidicolin and exert anti-proliferative activity in cells expressing BLM, but not in those lacking BLM. These data indicate that ML216 shows strong selectively for BLM in cultured cells. We discuss the potential utility of such a BLM-targeting compound as an anticancer agent.
There are a variety of lipoxygenases in the human body (hLO), each having a distinct role in cellular biology. Human reticulocyte 15-Lipoxygenase-1 (15-hLO-1), which catalyzes the dioxygenation of 1,4-cis,cis-pentadiene-containing polyunsaturated fatty acids, is implicated in a number of diseases including cancer, atherosclerosis, and neurodegenerative conditions. Despite the potential therapeutic relevance of this target, few inhibitors have been reported that are both potent and selective. To this end, we have employed a quantitative high-throughput (qHTS) screen against ~74,000 small molecules in search of reticulocyte 15-hLO-1 selective inhibitors. This screen led to the discovery of a novel chemotype for 15-hLO-1 inhibition, which displays nM potency and is >7,500-fold selective against the related isozymes, 5-hLO, platelet 12-hLO, epithelial 15-hLO-2, ovine cyclooxygenase-1 and human cyclooxygenase-2. In addition, kinetic experiments were performed which indicate that this class of inhibitor is tight binding, reversible, and appears not to reduce the active-site ferric ion.
A key challenge facing drug discovery
today is variability of the
drug target between species, such as with 12/15-lipoxygenase (12/15-LOX),
which contributes to ischemic brain injury, but its human and rodent
isozymes have different inhibitor specificities. In the current work,
we have utilized a quantitative high-throughput (qHTS) screen to identify
compound 1 (ML351), a novel chemotype for
12/15-LOX inhibition that has nanomolar potency (IC50 =
200 nM) against human 12/15-LOX and is protective against oxidative
glutamate toxicity in mouse neuronal HT22 cells. In addition, it exhibited
greater than 250-fold selectivity versus related LOX isozymes, was
a mixed inhibitor, and did not reduce the active-site ferric ion.
Lastly, 1 significantly reduced infarct size following
permanent focal ischemia in a mouse model of ischemic stroke. As such,
this represents the first report of a selective inhibitor of human
12/15-LOX with demonstrated in vivo activity in proof-of-concept mouse
models of stroke.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.